Zentek and McMaster Announced Results for Aptamer-Based Technology with Therapeutic Potential
Portfolio Pulse from Charles Gross
Zentek Ltd. (NASDAQ:ZTEK) announced successful testing of its aptamer platform, licensed from McMaster University, as a potential treatment for SARS-CoV-2 in pre-clinical animal models. The aptamers demonstrated similar efficacy against SARS-CoV-2 when compared to a commercial monoclonal antibody.
July 20, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zentek's successful pre-clinical trials of its aptamer platform could potentially lead to a new treatment for SARS-CoV-2, which may positively impact the company's stock.
The successful pre-clinical trials of Zentek's aptamer platform indicate potential for a new treatment for SARS-CoV-2. This could lead to increased investor interest and a potential rise in Zentek's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100